calendar
7,155 catalysts · 4,207 phase readout · 2,217 8k filing · 282 earnings · 172 phase 2 completion · 110 drug shortage · 73 phase 1 completion
7,155 catalysts · 4,207 phase readout · 2,217 8k filing · 282 earnings · 172 phase 2 completion · 110 drug shortage · 73 phase 1 completion
Ice Cream
Sponsor: MANKIND PHARMA. Form: SOLUTION/DROPS. Route: OPHTHALMIC
Sponsor: RK PHARMA. Form: TABLET. Route: ORAL
Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION
Status: Current. Reason: not specified. Form: Capsule
Status: Current. Reason: not specified. Form: Tablet
Status: Current. Reason: not specified. Form: Tablet
Status: Current. Reason: not specified. Form: Injection
Status: Current. Reason: not specified. Form: Injection
Status: Current. Reason: not specified. Form: Tablet
Status: Current. Reason: not specified. Form: Injection
Status: Current. Reason: not specified. Form: Injection
Status: Current. Reason: not specified. Form: Capsule
Status: Current. Reason: not specified. Form: Injection
Status: Current. Reason: not specified. Form: Tablet
Status: Current. Reason: not specified. Form: Injection
Status: Current. Reason: not specified. Form: Injection
Status: Current. Reason: not specified. Form: Concentrate
Status: Current. Reason: not specified. Form: Tablet
Status: Current. Reason: not specified. Form: Injection
Status: Current. Reason: not specified. Form: Injection
NS grant. $633,378. PI: Alba Miranda Azola
AI grant. $88,250. PI: Jennifer Lynn Hyde
AI grant. $440,211. PI: Julie Dunning Hotopp
ES grant. $605,091. PI: Yike Shen
NS grant. $429,000. PI: NAGI G AYAD
AI grant. $161,244. PI: TERESA GIL GIL
CA grant. $415,623. PI: STEPHEN J KADLECEK
AI grant. $267,000. PI: Qianxia Zhang
DK grant. $769,882. PI: Cary Ragan Boyd-Shiwarski
NR grant. $3,480,544. PI: Michelle Trivedi
ES grant. $795,869. PI: Sean M Harris
AI grant. $660,723. PI: Hongyan Guo
AI grant. $843,182. PI: Christopher F Basler
AT grant. $788,967. PI: ADAM L. Halberstadt
Canine milk replacer
Sponsor: EXTROVIS. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: QUAGEN. Form: SYRUP. Route: ORAL
Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: GLENMARK SPECLT. Form: CREAM. Route: TOPICAL
Sponsor: MARKSANS PHARMA. Form: CAPSULE, DELAYED RELEASE. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Status: Current. Reason: not specified. Form: Capsule